{"id":"recomon-epoetin-beta","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Hypertension"},{"rate":"5-15","effect":"Headache"},{"rate":"1-5","effect":"Thrombosis/thromboembolic events"},{"rate":"5-10","effect":"Injection site reactions"},{"rate":"5-10","effect":"Flu-like symptoms"},{"rate":"<1","effect":"Pure red cell aplasia (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epoetin beta is a glycoprotein hormone produced through recombinant DNA technology that mimics endogenous erythropoietin. It binds to EPO receptors on erythroid progenitor cells in the bone marrow, promoting their proliferation, differentiation, and maturation into mature red blood cells. This increases hemoglobin levels and oxygen-carrying capacity in patients with anemia.","oneSentence":"Recomon is a recombinant erythropoietin (EPO) that stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells to increase red blood cell production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:03.691Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Anemia in patients with cancer receiving chemotherapy"},{"name":"Anemia in patients undergoing major surgery"}]},"trialDetails":[{"nctId":"NCT01111630","phase":"PHASE4","title":"Study of Erythropoietin (EPO) Administration Schedule","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2009-10","conditions":"Chronic Renal Failure, Anaemia","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":491,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"recomon (Epoetin Beta)","genericName":"recomon (Epoetin Beta)","companyName":"JW Pharmaceutical","companyId":"jw-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Recomon is a recombinant erythropoietin (EPO) that stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells to increase red blood cell production. Used for Anemia associated with chronic kidney disease, Anemia in patients with cancer receiving chemotherapy, Anemia in patients undergoing major surgery.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}